our products
our products
information_top

Call us at:

(818)591-3030

USA

Click here to send us an email
tel_section

Diagnostic Automation Question & AnswerDiagnostic Automation Question & Answer Diagnostic Automation Articles Diagnostic Automation kit images Diagnostic Automation videos


Pregnancy Rapid tests

CA-12-5 ELISA kit

Name

CA-12-5 ELISA kit

Full name

Human CA-12-5 ELISA Test Kit

Category Name Cancer ELISA kits
Test 96
Method ELISA method: Enzyme Linked Immunosorbent Assay
Principle Sandwich Complex
Detection Range 0-400U/mL
Sample 50ul serum
Specificity 97%
Sensitivity 5U/mL
Total Time ~200 min
Shelf Life 12-14 Months from the manufacturing date

Item #:                    6502-16   Quantity:               

CA-12-5 ELISA kit


CA-12-5 ELISA kit

callback phone number email us


CA-12-5 ELISA kit description:




The CA-125 EIA test is an ELISA assay for the quantitative measurement of CA-12-5 in human serum. CA125 elisa kit is primarily intended for use as a monitoring and screening test.




Material Provided with CA125ELISA Kit:
1. Microtiter wells coated with Monoclonal Anti-CA-12-5 antibody
2. CA-12-5 Elisa Enzyme conjugate reagent
3. CA12-5 Elisa Test reference standards
4. TMB Substrate
5. CA 12-5 EIA Kit Stop solution
6. CA 12-5 EIA Kit Wash Buffer Concentrate 50X

Materials Required, not Provided:
1. Precision pipettes
2. Distilled or deionized water
3. EIA kit Microplate Washer
4. EIA kit Microplate Reader with a 450 nm




CA125ELISA Kit Background Information:
Cancer Antigen 125 (CA-12-5) is a surface antigen associated with epithelial ovarian cancer. Elevated serum CA-12-5 levels can be found in individuals with serious endometroid, clear-cell and undifferentiated ovarian carcinoma. Serum CA-12-5 levels higher than normal can also be found in individuals with adenocarcinoma of the fallopian tube endometrium, certain non- gynecologic malignancies and some non-malignant conditions. The serum CA-12-5 concentration is greater than 35 units per ml in about 60% of women with ovarian cancer. More than 80% of patients with disseminated ovarian cancer, have serum CA-12-5 concentrations greater than 35 units per ml. The serum CA-12-5 is elevated in 1% of normal healthy women, 3% of normal healthy women with benign ovarian diseases, and 6% of patients with non-malignant conditions including but not limited to first trimester pregnancy, menstruation, endometriosis, uterine fibrosis, hepatic diseases and inflammation of peritoneum, pericardium or pleura.




CA125ELISA Test Principle:
The CA-12-5 Quantitative Test Kit is based on a solid phase enzyme-linked immunosorbent assay. The assay system utilizes one monoclonal anti-CA-12-5 antibody for microtiter wells) immobilization and another monoclonal anti-CA 125 antibody in the antibody-enzyme horseradish peroxidase conjugate solution. The standards and patient serum are added to the CA-12-5 antibody coated microtiter wells. Then CA-12-5 antibody labeled with conjugate is added. If human CA-12-5 is present in the specimen, it will combine with the antibody on the well and the enzyme conjugate resulting in the CA-12-5 molecules being sandwiched between the solid phase and enzyme-linked antibodies. For additional details please refer to the instructions for use.




Notable features of Cancer ELISA Kits:
User-friendly directions and explanation of test procedures
Simple and safe reagent preparation
Clear instructions on specimen collection
Comprehensive package of required materials
Explicit quality control and storage guidelines
Reliable and easy-to-read test results

Product inserts for all Cancer ELISA kits follow a similar method. See the CA125 ELISA Kit product insert for specific details on preparation, procedures, quality control, and test result interpretation.



Diagnostic Automation Inc. also provides other Autoimmune Disease ELISA Kits. For more information about ELISA Kits, Rapid Tests, IFA Kits, CLIA Test Kits, or Serology tests, please see our website home page, or contact our Customer Service Representatives at 818-591-3030 .



Product Note:

This serum CA-12-5 test appears to be a useful tumor marker for patients in clinical remission, following treatment.